Yuan Yuan, He Xian, Liu Ping, Pu Dali, Shi Qiuling, Chen Jinyun, Teichmann Alexander T, Zhan Ping
Sichuan Provincial Center for Gynaecology and Breast Diseases, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou, 646000, Sichuan, China.
State Key Laboratory of Ultrasound in Medicine and Engineering, Chongqing Medical University, Chongqing, 400016, China.
Arch Gynecol Obstet. 2023 Apr;307(4):1037-1045. doi: 10.1007/s00404-022-06840-6. Epub 2022 Dec 16.
To evaluate the feasibility and effectiveness of single ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation in managing placenta accreta spectrum (PAS) disorder.
We retrospectively analyzed 40 PAS patients between April 2017 and October 2021. All the patients received one session of HIFU treatment. Regular follow-up was done after HIFU treatment until normal menstruation returned and placental tissue disappeared. The patient's reproductive-related outcomes were obtained through telephone interviews.
The median follow-up time for the 40 patients was 30.50 (15.75-44.00) months and the mean placental tissue elimination time was 45.29 ± 33.32 days. The mean duration of bloody lochia was 13.43 ± 10.01 days, with no incidences of severe bleeding. Notably, Linear regression analysis showed that the residual placenta volume before HIFU was a factor affecting the duration of bloody lochia after HIFU (R2 = 0.284, B = 0.062, P = 0.000). The normal menstrual return time was 58.71 ± 31.14 days. One (2.50%) patient developed an infection. Two (5.00%) patients were subjected to ultrasound-guided suction curettage for persistent vaginal discharge for more than one month without infection. Notably, 7 of the 18 patients who expressed reproductive plans became pregnant during the 4 to 53 months of follow-up without placental abnormalities. The remaining 11 patients were on contraceptives.
Single HIFU is an effective treatment option for managing PAS. However, future studies on further treatment strategies to reduce complications and promote patient recovery after HIFU ablation are desirable.
评估单次超声引导下高强度聚焦超声(USgHIFU)消融治疗胎盘植入谱系疾病(PAS)的可行性和有效性。
回顾性分析2017年4月至2021年10月期间的40例PAS患者。所有患者均接受了一次HIFU治疗。HIFU治疗后进行定期随访,直至月经恢复正常且胎盘组织消失。通过电话访谈获得患者的生殖相关结局。
40例患者的中位随访时间为30.50(15.75 - 44.00)个月,平均胎盘组织清除时间为45.29±33.32天。平均血性恶露持续时间为13.43±10.01天,无严重出血事件发生。值得注意的是,线性回归分析显示,HIFU治疗前的残留胎盘体积是影响HIFU治疗后血性恶露持续时间的一个因素(R2 = 0.284,B = 0.062,P = 0.000)。月经恢复正常时间为58.71±31.14天。1例(2.50%)患者发生感染。2例(5.00%)患者因持续阴道流血超过1个月且无感染而接受超声引导下刮宫术。值得注意的是,18例有生育计划的患者中有7例在随访的4至53个月内怀孕,且无胎盘异常。其余11例患者采取避孕措施。
单次HIFU是治疗PAS的有效选择。然而,未来需要进一步研究减少并发症及促进HIFU消融术后患者恢复的治疗策略。